Genprex, Inc. 8-K

What Happened

• On March 18, 2026, Genprex announced that research collaborators will present positive preclinical data for its lead gene therapy candidate REQORSA (quaratusugene ozeplasmid, “Quar Oze” / TUSC2) at the AACR Annual Meeting, April 17–22, 2026 in San Diego.
• The company highlighted three Genprex-supported posters showing: (1) identification of TROP2 (low) and PTEN (high) as potential biomarkers of primary resistance to TUSC2 in NSCLC models; (2) Quar Oze induces apoptosis and substantially shrinks tumors in ALK+ models and enhances activity when combined with the ALK inhibitor alectinib; and (3) TUSC2 restoration boosts natural killer (NK) cell cytotoxicity and can drive complete tumor regression in mouse models.

Key Details

• Filing date: March 18, 2026; AACR meeting: April 17–22, 2026 (San Diego).
• Preclinical results: 50% of a 10-cell-line panel and 50% of 12 PDX-derived organoids showed primary resistance to TUSC2; 20–30% of tumors in several acquired-resistance xenograft models were resistant after TUSC2 treatment.
• ALK+ models: Alectinib alone produced ~60% tumor shrinkage in a sensitive model; Quar Oze alone and Quar Oze + alectinib produced ~79% shrinkage (p=0.0135 vs control), with the combo showing synergistic effects and significantly improved survival in a resistant model (p=0.0001 vs control).
• Immunology data: Therapeutic Quar Oze led to complete tumor regression in 67% of Tusc2 KO mice and 33% of wild‑type mice; Quar Oze increased NK cell granzyme B, perforin, degranulation and proliferation.

Why It Matters

• These are preclinical findings that could influence Genprex’s development strategy: identification of TROP2 and PTEN as potential biomarkers may help refine patient selection, and the observed synergy with alectinib supports exploring REQORSA as an adjunct in ALK+ NSCLC.
• For investors, the results signal scientific progress and potential paths for clinical trial design, but they are not clinical efficacy data and do not guarantee regulatory or commercial success. The company’s filing includes standard forward‑looking language noting risks and uncertainties.